0 11 Suppression suppression NN 12 14 of of IN 15 24 NF-kappaB NF-kappaB NNP 25 35 activation activation NN 36 38 in in IN 39 45 normal normal JJ 46 47 T t NN 48 53 cells cell NNS 54 56 by by IN 57 68 supernatant supernatant JJ 69 74 fluid fluid NN 75 79 from from IN 80 85 human human JJ 86 91 renal renal JJ 92 96 cell cell NN 97 107 carcinomas carcinoma NNS 107 108 . . . 110 111 T t NN 112 123 lymphocytes lymphocyte NNS 124 128 from from IN 129 137 patients patient NNS 138 142 with with IN 143 148 renal renal JJ 149 153 cell cell NN 154 163 carcinoma carcinoma NN 164 165 ( ( ( 165 168 RCC RCC NNP 168 169 ) ) ) 170 174 show show VBP 175 182 reduced reduce VBN 183 189 immune immune JJ 190 198 function function NN 199 202 and and CC 203 211 impaired impaired JJ 212 222 activation activation NN 223 225 of of IN 226 229 the the DT 230 243 transcription transcription NN 244 250 factor factor NN 250 251 , , , 252 261 NF-kappaB NF-kappaB NNP 261 262 . . . 263 265 We we PRP 266 276 determined determine VBD 277 280 the the DT 281 290 mechanism mechanism NN 291 293 of of IN 294 303 NF-kappaB NF-kappaB NNP 304 315 suppression suppression NN 316 318 in in IN 319 320 T t NN 321 326 cells cell NNS 327 329 of of IN 330 333 RCC RCC NNP 334 341 patient patient NN 342 345 and and CC 346 356 determined determine VBD 357 364 whether whether IN 365 376 supernatant supernatant JJ 377 382 fluid fluid NN 383 387 from from IN 388 391 RCC RCC NNP 392 400 explants explant NNS 401 402 ( ( ( 402 407 RCC-S RCC-S NNP 407 408 ) ) ) 409 416 induced induce VBD 417 420 the the DT 421 425 same same JJ 426 435 phenotype phenotype NN 436 438 of of IN 439 448 NF-kappaB NF-kappaB NNP 449 460 suppression suppression NN 461 463 in in IN 464 470 normal normal JJ 471 472 T t NN 473 478 cells cell NNS 479 483 that that WDT 484 486 is be VBZ 487 495 observed observe VBN 496 498 in in IN 499 506 patient patient NN 507 508 T t NN 509 514 cells cell NNS 514 515 . . . 516 519 The the DT 520 527 pattern pattern NN 528 530 of of IN 531 545 kappaB-binding kappab-binding JJ 546 554 activity activity NN 555 557 in in IN 558 559 T t NN 560 565 cells cell NNS 566 568 of of IN 569 572 RCC RCC NNP 573 580 patient patient NN 581 584 was be VBD 585 592 altered alter VBN 593 595 as as IN 596 604 compared compare VBN 605 607 to to TO 608 612 that that DT 613 617 seen see VBN 618 620 in in IN 621 622 T t NN 623 628 cells cell NNS 629 637 obtained obtain VBN 638 642 from from IN 643 649 normal normal JJ 650 660 volunteers volunteer NNS 660 661 . . . 662 664 In in IN 665 669 some some DT 670 678 patients patient NNS 678 679 , , , 680 682 no no DT 683 693 activation activation NN 694 696 of of IN 697 719 RelA/NFkappaB1-binding rela/nfkappab1-binding JJ 720 728 activity activity NN 729 732 was be VBD 733 743 detectable detectable JJ 743 744 , , , 745 750 while while IN 751 753 in in IN 754 760 others other NNS 761 775 kappaB-binding kappab-binding JJ 776 784 activity activity NN 785 788 was be VBD 789 797 modestly modestly RB 798 805 induced induce VBN 806 809 but but CC 810 813 the the DT 814 822 duration duration NN 823 826 was be VBD 827 834 reduced reduce VBN 834 835 . . . 836 848 IkappaBalpha IkappaBalpha NNP 849 852 was be VBD 853 861 degraded degrade VBN 862 870 normally normally RB 871 880 following follow VBG 881 892 stimulation stimulation NN 893 895 in in IN 896 900 both both CC 901 907 normal normal JJ 908 916 controls control NNS 917 920 and and CC 921 922 T t NN 923 928 cells cell NNS 929 933 from from IN 934 937 RCC RCC NNP 938 946 patients patient NNS 946 947 . . . 948 953 RCC-S RCC-S NNP 954 957 did do VBD 958 961 not not RB 962 967 alter alter VB 968 971 the the DT 972 983 cytoplasmic cytoplasmic JJ 984 990 levels level NNS 991 993 of of IN 994 998 RelA RelA NNP 999 1002 and and CC 1003 1013 NF-kappaB1 NF-kappaB1 NNP 1014 1017 but but CC 1018 1021 did do VBD 1022 1030 suppress suppress VB 1031 1036 their their PRP$ 1037 1044 nuclear nuclear JJ 1045 1057 localization localization NN 1058 1061 and and CC 1062 1071 inhibited inhibit VBD 1072 1075 the the DT 1076 1086 activation activation NN 1087 1089 of of IN 1090 1105 RelA/NF-kappaB1 rela/nf-kappab1 NN 1106 1113 binding binding NN 1114 1123 complexes complex NNS 1123 1124 . . . 1125 1130 These these DT 1131 1138 results result NNS 1139 1143 show show VBP 1144 1148 that that IN 1149 1154 RCC-S rcc-s NNS 1155 1158 can can MD 1159 1165 induce induce VB 1166 1168 in in IN 1169 1175 normal normal JJ 1176 1177 T t NN 1178 1183 cells cell NNS 1184 1187 the the DT 1188 1192 same same JJ 1193 1202 phenotype phenotype NN 1203 1205 of of IN 1206 1214 impaired impaired JJ 1215 1224 NF-kappaB NF-kappaB NNP 1225 1235 activation activation NN 1236 1240 that that WDT 1241 1243 is be VBZ 1244 1252 detected detect VBN 1253 1255 in in IN 1256 1257 T t NN 1258 1263 cells cell NNS 1264 1266 of of IN 1267 1270 RCC RCC NNP 1271 1278 patient patient NN 1278 1279 . . . 1280 1282 It it PRP 1283 1287 also also RB 1288 1295 appears appear VBZ 1296 1300 that that IN 1301 1310 NF-kappaB NF-kappaB NNP 1311 1322 suppression suppression NN 1323 1325 by by IN 1326 1331 RCC-S RCC-S NNP 1332 1335 may may MD 1336 1346 contribute contribute VB 1347 1349 to to TO 1350 1353 the the DT 1354 1371 immunosuppression immunosuppression NN 1372 1374 of of IN 1375 1379 host host NN 1380 1388 immunity immunity NN 1388 1389 . . .